Lineage CEO Brian Culley said his company and Genentech sought to finalize their collaboration in 2021, to take advantage of the window presented by Lineage completing enrollment in the Phase I/IIa trial, and planning its next clinical study. How quickly that and other trials get launched will be up to Genentech. Time will tell whether Lineage will pursue those other disease and applications alone or with additional biopharma partners . . .